Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer

Publisher： Karger

E-ISSN： 1423-0232|79|1-2|98-104

ISSN： 0030-2414

Source： Oncology, Vol.79, Iss.1-2, 2010-11, pp. : 98-104

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oral Trofosfamide in Elderly and/or Heavily Pretreated Patients with Metastatic Lung Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 4, 2000-09 ,pp. : 341-344

Karger

Access to resources Recommend Favorite

Long‐term survival with bevacizumab in heavily pretreated and platinum‐resistant mucinous ovarian cancer: A case report

By  

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (ELECTRONIC), Vol. 44, Iss. 2, 2018-02 ,pp. : 347-351

John Wiley & Sons Inc

Access to resources Recommend Favorite

Metronomic Oral Cyclophosphamide in Patients with Advanced Solid Tumors

By  

Oncology Research and Treatment, Vol. 35, Iss. 1-2, 2012-01 ,pp. : 35-38

Karger

Access to resources Recommend Favorite

Weekly Cisplatin plus Capecitabine in Metastatic Breast Cancer Patients Heavily Pretreated with both Anthracycline and Taxanes

By  

Oncology, Vol. 69, Iss. 5, 2005-12 ,pp. : 408-413

Karger

Access to resources Recommend Favorite

Phase II Study of Pegylated Liposomal Doxorubicin in Heavily Pretreated Epithelial Ovarian Cancer Patients

By  

Oncology, Vol. 67, Iss. 3-4, 2004-11 ,pp. : 243-249

Karger

Access to resources Recommend Favorite